Table 2.
Potential immune checkpoint inhibitors under clinical trials enrolled in ClinicalTrials.gov. The search conditions were as follows: status, recruiting and not yet recruiting studies; condition of disease, cancer; other terms, PD-1 or PD-L1 or CTLA-4 or checkpoint.
| ClinicalTrials.gov Identifier | Purpose | Study Population | Interventions | Status | Phase | |
|---|---|---|---|---|---|---|
| 1 | NCT02694822 | Evaluation | Advanced solid cancers and Advanced solid cancers refractory to PD-1 | Drug: AGEN1884 | Active, not recruiting | Phase1/2 |
| 2 | NCT03989362 | Combination | Cancer | Drug: Vopratelimab and Ipilimumab | Active, not recruiting | Phase 2 |
| 3 | NCT03515629 | Combination | NSCLC | Drug: REGN2810/Ipilimumab, REGN2810/chemo/Ipilimumab, and Pembrolizumab | Active, not recruiting | Phase 3 |
| 4 | NCT04172454 | Evaluation | Advanced Solid Tumors Melanoma | Drug: AK104 | Not yet recruiting | Phase 1B/2 |
| 5 | NCT03527251 | Combination | NSCLC | Drug: Ipilimumab, SHR-1210 | Unknown | Phase 1 |
| 6 | NCT04326257 | Combination | HNSCC | Drug: Nivolumab/Relatlimab and Nivolumab/Ipilimumab | Recruiting | Phase 2 |
| 7 | NCT04868708 | Combination | Recurrent or Metastatic Cervical Cancer | Biological: AK104 and Bevacizumab, Drug: Paclitaxel and Cisplatin or Carboplatin | Not yet recruiting | Phase 2 |
| 8 | NCT03430063 | Combination | Advanced NSCLS | Drug: SDREGN2810, SDREGN2810/Ipilimumab, and HDREGN2810 | Active, not recruiting | Phase 2 |
| 9 | NCT04140526 | Combination | NSCLC/Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic RCC/Metastatic CRC, Sarcomas/Metastatic Prostate Cancer, Ovarian Cancer/SCLC, Metastatic Breast Cancer | Drug: ONC-392 and Pembrolizumab | Recruiting | Phase 1 |
| 10 | NCT04544644 | Combination | NSCLC | Drug: AK104/Anlotinib | Not yet recruiting | Phase 2 |
| 11 | NCT02403193 | Evaluation and Combination | NSCLC | Drug: PBF-509_(80~640 mg), PBF-509 (160~640 mg) + PDR001, RP2D with ICIs naïve, Experimental: RP2D with ICIs treated | Active, not recruiting | Phase1/2b |
| 12 | NCT02535078 | Combination | Malignant Melanoma | Drug: IMCgp100, Durvalumab, Tremelimumab | Active, not recruiting | Phase 1B/2 |
| 13 | NCT03388632 | Combination | Metastatic Solid Tumors and Treatment-Refractory Cancers | Drug: rhIL-15, Ipilimumab, and Nivolumab | Recruiting | Phase 1 |
| 14 | NCT03608046 | Combination | Colorectal Neoplasms, Malignant | Drug: Avelumab, Cetuximab Injection, Irinotecan | Recruiting | Phase 2 |
| 15 | NCT03040791 | Expansion | Prostate Cancer | Drug: Nivolumab | Recruiting | Phase 2 |
| 16 | NCT02821754 | Combination | Biliary Tract Neoplasms, Liver Cancer, HCC, Cholangiocarcinoma, and Bile Duct Cancer | Drug: Durvalumab and Tremelimumab, Procedure: TACE, RFA, Cryoablation | Recruiting | Phase 2 |
| 17 | NCT03019003 | Combination | Head and Neck Cancer | Drug: Oral Decitabine and Durvalumab | Recruiting | Phase 1 and Phase 2 |
| 18 | NCT03202758 | Combination | Metastatic CRC | Drug: Durvalumab/Tremelimumab/FOLFOX | Unknown | Phase 1 and Phase 2 |
| 19 | NCT02938793 | Combination | Cancer | Drug: Durvalumab and Tremelimumab | Recruiting | Phase 2 |
| 20 | NCT03925246 | Expansion | High Grade Glioma/ Brain Cancer | Drug: Nivolumab | Active, not recruiting | Phase 2 |
| 21 | NCT03084471 | Combination | Advanced Solid Malignancies | Biological: MEDI4736 and MEDI4736/Tremelimumab | Active, not recruiting | Phase 3 |
| 22 | NCT03608046 | Combination | Colorectal Neoplasms, Malignant | Drug: Avelumab, Cetuximab Injection, and Irinotecan | Recruiting | Phase 2 |
| 23 | NCT03409198 | Combination | Breast Cancer, Hormone Receptor Positive Tumor, and Metastatic Breast Cancer | Drug: Ipilimumab, Nivolumab, Pegylated liposomal doxorubicin, and Cyclophosphamide | Active, not recruiting | Phase 2 |
| 24 | NCT04319224 | Combination | Cancer | Drug: Vopratelimab, Ipilimumab, Nivolumab | Recruiting | Phase 1 and Phase 2 |
| 25 | NCT03526185 | Combination | Metastatic Melanoma | Drug: Tumor Infiltrating Lymphocytes and Nivolumab/Ipilimumab | Active, not recruiting | Early Phase 1 |
| 26 | NCT03911557 | Combination | Tumor, Solid | Drug: Durvalumab/Tremelimumab | Recruiting | Phase 2 |
| 27 | NCT03308396 | Combination | Advanced Kidney Cancer, Kidney Cancer, and Clear Cell RCC | Drug: Guadecitabine, Durvalumab | Active, not recruiting | Phase 1 and Phase 2 |
| 28 | NCT03186326 | Expansion | Metastatic CRC MSI |
Drug: FOLFOX regimen, FOLFIRI Protocol, Avelumab, Panitumumab, Cetuximab, Bevacizumab, and Aflibercept | Active, not recruiting | Phase 2 |
| 29 | NCT03206073 | Combination | CRC, Colorectal Carcinoma, Colorectal Adenocarcinoma, Refractory Cancer, and Colorectal Neoplasms | Drug: Durvalumab and Tremelimumab, Biological: Pexa-Vec | Active, not recruiting | Phase 1 and Phase 2 |
| 30 | NCT03373760 | Combination | Recurrent Squamous Cell Lung Carcinoma and Stage IV Squamous Cell Lung Carcinoma AJCC v7 | Biological: Durvalumab and Tremelimumab, Other: Laboratory Biomarker Analysis | Active, not recruiting | Phase 2 |
| 31 | NCT03959293 | Combination | Gastric Adenocarcinoma and Gastric Cancer | Drug: Durvalumab, Tremelimumab, and FOLFIRI Protocol | Recruiting | Phase 2 |
| 32 | NCT03693612 | Combination | Neoplasms | Drug: Feladilimab, Tremelimumab, Docetaxel, Paclitaxel, and Cetuximab | Active, not recruiting | Phase 1 and Phase 2 |
| 33 | NCT03755739 | Administration | Hepatocarcinoma/Lung Cancer, Melanoma/Renal Cancer, Head and Neck Cancer, and Pancreas Cancer/Ovarian Cancer, CRC/Cervical Cancer/Breast Cancer | Drug: ICIs | Recruiting | Phase 2 and Phase 3 |
| 34 | NCT03033576 | Combination | Advanced Melanoma, Melanoma of Unknown Primary, Mucosal Melanoma, Refractory Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Cutaneous Melanoma, and Unresectable Melanoma | Biological: Ipilimumab and Nivolumab | Active, not recruiting | Phase 2 |
| 35 | NCT02821754 | Combination | Biliary Tract Neoplasms, Liver Cancer/HCC, Cholangiocarcinoma, and Bile Duct Cancer | Drug: Durvalumab and Tremelimumab, Procedure: TACE, RFA, and Cryoablation | Recruiting | Phase 2 |
Administration, clinical trials for comparison of efficacy following different administration; AGEN1884, anti-CTLA-4 antibody; AK104, humanized IgG1 tetrameric PD-1/CTLA-4 bispecific antibody; chemo, chemotherapy; combination, clinical trials for novel drug combination regimen; CRC, colorectal cancer; evaluation, clinical trials for development of novel drug candidates; expansion, clinical trials for expansion of indication; FOLFOX, combination chemotherapy made up of folinic acid, fluorouracil, and oxaliplatin; HCC, hepatocellular carcinoma; HDREGN2810, high dose cemiplimab; HNSCC, head and neck squamous cell carcinoma; ICI, immune checkpoint inhibitor; IMCgp100, engineered T cell receptor specific for a peptide antigen derived from the protein gp100; MEDI4736, durvalumab; NSCLC, non-small cell lung cancer; ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody; PBF-509, Adenosine A2a receptor antagonist; PDR001, anti-PD-1 antibody; pexa-Vec, a thymidine kinase gene-inactivated oncolytic vaccinia virus engineered for the expression of transgenes encoding human granulocyte-macrophage colony-stimulating factor (GM-CSF) and beta-galactosidase; RCC, renal cell carcinoma; REGN2810, cemiplimab; RFA, Radiofrequency ablation; rhIL-15, recombinant interleukin-15; RP2D, PBR-509 + PDR001; SCLC, small cell lung cancer; SDREGN2810, standard dose cemiplimab; SHR-1210, anti-PD-1 antibody; TACE, Transarterial chemoembolization.